Aim: The aim of this study is to develop a sensitive, specific, rapid, and precise reverse- phase high-performance liquid chromatography (RP-HPLC) method and validate it to determine the Roflumilast in rat plasma. Background: This study was aimed at developing a simple HPLC method for the detection of Roflumilast in rat plasma after ingestion of nanoparticles into the rat. A bioanalytical method was developed and validated. Methodology: The drug sample (Roflumilast) was eluted isocratically using a mobile phase of Ammonium acetate buffer (pH = 7.0), acetonitrile, and methanol (20:40:40, v/v/v) made up the mobile phase on a Phenomenex C-18 (150mm x 4.68mm pore size 5-micron analytical column. The drug was quantitatively determined at a UV wavelength of 254 nm using a standard calibration curve spanning the range of 1.5, 3.0, 4.5, 6.0, 7.5μg/mL-1 Results: The results showed that the limits of quantitation (LOQ) and detection (LOD) were 0.18 μg/ml and 0.54μg/ml, respectively. For both the intra-day and inter-day analysis, relative standard deviation (% RSD) was less than 2%, and the drug’s percentage accuracy was between 96% and 98%. Conclusion: As per the established protocols, the developed method was quantitatively assessed for its intended use in terms of specificity, linearity, accuracy, precision, robustness, and sensitivity analysis. Roflumilast-loaded nanoparticles were effectively used to determine the drug entrapment efficiency using the currently validated RP-HPLC method. Besides, highly efficient drug extraction from plasma was attained, and mobile phase composition was suitable to the pharmacokinetic study of Roflumilast-loaded nanoparticles in rats. other: NA
Read full abstract